Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company. The Company develops and commercializes a series of products for various types of cardiovascular disease and associated co-morbidities, including coronary heart disease (CHD), stroke, heart failure and diabetes, by leveraging its artificial intelligence (AI)-driven Integrated Genetic-Epigenetic Engine. Its first product, Epi+Gen CHD, is an epigenetics-based clinical blood test capable of assessing near-term (three-year) risk for CHD, and its second product, PrecisionCHD, is an epigenetics-based clinical blood test for the detection of CHD. CardioInnovate360 is a research use only (RUO) solution to support the discovery, development, and validation of biopharmaceuticals for the assessment and management of cardiovascular diseases. HeartRisk is a cardiovascular risk intelligence platform that combines insights from anonymized and aggregated clinical cardiovascular data.
Símbolo de cotizaciónCDIO
Nombre de la empresaCardio Diagnostics Holdings Inc
Fecha de salida a bolsaNov 23, 2021
Director ejecutivoDogan (Meeshanthini V)
Número de empleados13
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 23
Dirección311 W. Superior Street
CiudadCHICAGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal60645
Teléfono18552269991
Sitio Web
Símbolo de cotizaciónCDIO
Fecha de salida a bolsaNov 23, 2021
Director ejecutivoDogan (Meeshanthini V)
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos